US 2024/0042003 A1 · CROSS-PROTECTIVE ANTIGENS FOR VACCINATION

Abstract

A method of immunizing a mammalian patient against infection by a bacterial pathogen involves administering a pertussis or Pseudomonas antigen to the mammalian patient. The pertussis antigen is least one of a chaperonin protein GroEL from Bordetella pertussis, or a fragment thereof; and an OmpA protein of Bordetella pertussis, or a fragment thereof. The Pseudomonas antigen is least one of a chaperonin protein GroEL from Pseudomonas aeruginosa, or a fragment thereof; and an OprF protein from Pseudomonas aeruginosa, or an OmpA-domain fragment thereof. The bacterial pathogen expresses a protein having at least 45% identity to the pertussis antigen. The bacterial pathogen may be a gram-negative bacteria. The bacterial pathogen may be a bacteria from a genus Escherichia, a genus Enterococcus, a genus Staphylococcus, a genus Klebsiella, a genus Acinetobacter, and a genus Enterobacter.

Claims20

Dependent claims

A method of immunizing a mammalian patient against infection by a bacterial pathogen, comprising administering a pertussis antigen to the mammalian patient,

wherein the pertussis antigen is least one of:
a chaperonin protein GroEL from Bordetella pertussis, or a fragment thereof;
an OmpA protein of Bordetella pertussis, or a fragment thereof;
and
wherein the bacterial pathogen expresses a protein having at least 45% identity to the pertussis antigen.

2 more elements

A method of immunizing a mammalian patient against infection by a bacterial pathogen, comprising administering a Pseudomonas antigen to the mammalian patient,

wherein the Pseudomonas antigen is least one of:
a chaperonin protein GroEL from Pseudomonas aeruginosa, or a fragment thereof;
an OprF protein from Pseudomonas aeruginosa, or a fragment thereof;
and
wherein:
the bacterial pathogen expresses a protein having at least 45% identity to the Pseudomonas antigen.

3 more elements

A therapeutically effective antibody, wherein the antibody is selected from the group consisting of:

an antibody generated against B. pertussis GroEL having at least 85% identity to SEQ ID NO:
16 or a fragment thereof, wherein the antibody generated against B. pertussis GroEL has cross reactivity against P. aeruginosa bacteria expressing P. aeruginosa GroEL;
an antibody generated against P. aeruginosa GroEL having at least 85% identity to SEQ ID NO:
14 or a fragment thereof, wherein the antibody generated against P. aeruginosa GroEL has cross reactivity against other species of bacteria expressing GroEL;
and
an antibody generated against B. pertussis OmpA having at least 85% identity to SEQ ID NO:
8 or a fragment thereof, wherein the antibody generated against B. pertussis OmpA has cross reactivity against other species of bacteria.

4 more elements

Dependencies are inferred from the claim text.

Cross-protective antigens for vaccination

Life of this patent

Cross-protective antigens for vaccination

Life of this patent

Abstract

Claims20